<div id="readability-page-1"><div>SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of scPharmaceuticals Inc. (NASDAQ: SCPH) to MannKind Corporation is fair to scPharmaceuticals shareholders. Under the terms of the proposed transaction, scPharmaceuticals shareholders would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash. Halper Sadeh encourages scPharmaceuticals shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether scPharmaceuticals and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for scPharmaceuticals shareholders; (2) determine whether MannKind is underpaying for scPharmaceuticals; and (3) disclose all material information necessary for scPharmaceuticals shareholders to adequately assess and value the merger consideration. On behalf of scPharmaceuticals shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTA4MjU3OTkwNzlyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTA4MjU3OTkwNzlyMQ"/> Halper Sadeh LLC One World Trade Center 85th Floor New York, NY 10007 Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 sadeh@halpersadeh.com zhalper@halpersadeh.com https://www.halpersadeh.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250825799079/en/</div></div>

SCPH

Halper Sadeh LLC 正在調查 scPharmaceuticals Inc.（納斯達克代碼：SCPH）以每股 5.35 美元加上或有價值權利出售給 MannKind Corporation 的提議是否公平。該公司質疑 scPharmaceuticals 董事會是否以股東的最佳利益行事，以及 MannKind 是否支付不足。他們可能會尋求提高對價和為股東提供更多披露。Halper Sadeh LLC 以成功收費的方式運營，代表因公司不當行為而受到影響的投資者

SCPH 股票警報：Halper Sadeh LLC 正在調查 scPharmaceuticals Inc.的出售是否公平對待股東